These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
    Author: Chuang P, Langone AJ.
    Journal: Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931.
    Abstract:
    Hyperlipidemia is common after renal transplantation. On the basis of current lipid guidelines, the majority of renal transplant recipients should have plasma low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL. Even with statin (HMG-CoA [3-hydroxy-3-methylglutaryl CoA] reductase inhibitor) therapy, a significant number of renal transplant recipients have LDL-C levels >100 mg/dL. We report that ezetimibe, a novel inhibitor of intestinal cholesterol absorption, was well tolerated and effectively reduced the LDL-C level to <100 mg/dL in our cohort of renal transplant recipients with persistently elevated LDL-C levels during treatment with maximally tolerated statin medications.
    [Abstract] [Full Text] [Related] [New Search]